{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:17:31Z","timestamp":1780417051031,"version":"3.54.1"},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,6,26]],"date-time":"2009-06-26T00:00:00Z","timestamp":1245974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2009,10]]},"abstract":" WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p>\u2022\u2003Spironolactone is known to have antiandrogenic features and agonist activity at progesterone receptors, which are responsible for several of its hormonal side\u2010effects.<\/jats:p>\u2022\u2003The potential unfavourable influences of this medication on serum lipoproteins have long been a concern but literature lacks sufficient data on this issue.<\/jats:p> WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p>\u2022\u2003Spironolactone can adversely affect serum lipids by decreasing high\u2010density lipoprotein and increasing low\u2010density lipoprotein in women treated for hirsutism on a short\u2010term basis.<\/jats:p><\/jats:sec>AIMS<\/jats:title>To investigate the effects of spironolactone on serum lipids in women with hirsutism over a 3\u2010month period.<\/jats:p><\/jats:sec>METHODS<\/jats:title>In a prospective setting, 27 hirsute women (20 with polycystic ovary syndrome and seven with idiopathic hirsutism) with a mean age of 23.0\u2003\u00b1\u20035.1 years were studied at baseline and 3 months after receiving a daily dose of 100\u2003mg of spironolactone. Patients did not receive any other medications and did not go through a specific diet during the study. Lipid profile, fasting blood glucose, testosterone, dehydroepiandrosterone sulphate (DHEAS) and prolactin (PRL) were measured at baseline and 3 months after therapy.<\/jats:p><\/jats:sec>RESULTS<\/jats:title>Mean body mass index of patients was 26.1\u2003\u00b1\u20035.1\u2003kg\u2003m\u22122<\/jats:sup> before treatment and 25.9\u2003\u00b1\u20035.7\u2003kg\u2003m\u22122<\/jats:sup> after treatment (NS). The therapy was associated with a significant decline of mean high\u2010density lipoprotein (HDL), 39.5\u2003mg\u2003dl\u22121<\/jats:sup>[95% confidence interval (CI) 35.6, 43.4]vs.<\/jats:italic> 32.2\u2003mg\u2003dl\u22121<\/jats:sup> (95% CI 29.2, 35.2), and a significant increase in mean low\u2010density lipoprotein (LDL), 133.1\u2003mg\u2003dl\u22121<\/jats:sup> (95% CI 120.2, 146) vs.<\/jats:italic> 150.8\u2003mg\u2003dl\u22121<\/jats:sup> (95% CI 139.1, 162.5), and cholesterol\/HDL ratio, 5 (95% CI 4.4, 5.6) vs.<\/jats:italic> 6.4 (95% CI 5.7, 7.1) (P<\/jats:italic>\u2003<\u20030.05). No significant change was noted in total cholesterol, triglyceride or fasting blood glucose levels. Serum values of testosterone, DHEAS and PRL decreased significantly after 3 months of therapy (P<\/jats:italic>\u2003<\u20030.05).<\/jats:p><\/jats:sec>CONCLUSIONS<\/jats:title>Spironolactone might have adverse effects on serum lipoprotein levels by increasing LDL and decreasing HDL over a short course of treatment. While treating hirsutism with spironolactone, special care should be given to women with metabolic disorders such as dyslipidaemia.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2009.03483.x","type":"journal-article","created":{"date-parts":[[2009,6,26]],"date-time":"2009-06-26T10:03:48Z","timestamp":1246010628000},"page":"634-637","source":"Crossref","is-referenced-by-count":16,"title":["Short term effects of spironolactone on blood lipid profile: a 3\u2010month study on a cohort of young women with hirsutism"],"prefix":"10.1111","volume":"68","author":[{"given":"Manouchehr","family":"Nakhjavani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Esteghamati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrshad","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simindokht","family":"Nosratian\u2010Jahromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvin","family":"Pasalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,10,15]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2003.10.005"},{"key":"e_1_2_6_3_2","first-page":"377","volume-title":"Polycystic Ovary Syndrome","author":"Zawadski JK","year":"1992"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0015-0282(16)48972-7","article-title":"The effects of spironolactone on adrenal steroidogenesis in hirsute women","volume":"44","author":"Searafini P","year":"1985","journal-title":"Fertil Steril"},{"key":"e_1_2_6_5_2","first-page":"429","article-title":"Therapeutic effects of spironolactone in polycystic ovary syndrome","volume":"61","author":"Milewicz A","year":"1983","journal-title":"Obstet Gynecol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1983.tb03684.x"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(87)91030-7"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345529"},{"key":"e_1_2_6_9_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0960-0760(02)00154-1","article-title":"On the inhibitory action of 29 drugs having side effect gynecomastia on estrogen production","volume":"82","author":"Satoh T","year":"2002","journal-title":"J Steroid Biochem Mol Biol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2008.02.001"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.2.5.672"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1984.00350160058010"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0010-7824(91)90112-S"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/j.1552-4604.1991.tb01903.x","article-title":"Hydrochlorothiazide versus spironolactone: long\u2010term metabolic modifications in patients with essential hypertension","volume":"31","author":"Garc\u00e1 Puig J","year":"1991","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.3109\/09513599609012316"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2009.03483.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2009.03483.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:14:46Z","timestamp":1697411686000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2009.03483.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["10.1111\/j.1365-2125.2009.03483.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03483.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}